146 Biotechnology Stocks Moving In Thursday's Session

Gainers

• Sierra Oncology, Inc. SRRA stock increased by 3638.9% to $13.00 during Thursday's regular session. The most recent rating by Oppenheimer, on December 06, is at Outperform, with a price target of $1.20.

• Innovate, Inc. INNT stock increased by 43.1% to $0.94.

• Kaleido Biosciences, Inc. KLDO shares moved upwards by 34.0% to $7.69.

• Leap Therapeutics, Inc. LPTX shares surged 25.7% to $2.25. The most recent rating by Raymond James, on January 08, is at Outperform, with a price target of $2.50.

• EyePoint Pharmaceuticals, Inc. EYPT stock surged 18.1% to $1.90. According to the most recent rating by H.C. Wainwright, on November 11, the current rating is at Neutral.

• LogicBio Therapeutics, Inc. LOGC stock moved upwards by 16.5% to $8.90.

• Soligenix, Inc. SNGX shares moved upwards by 15.2% to $2.81.

• Miragen Therapeutics, Inc. MGEN stock surged 14.7% to $0.68. The most recent rating by Baird, on December 12, is at Neutral, with a price target of $1.00.

• Evelo Biosciences, Inc. EVLO shares surged 14.5% to $6.15.

• Acorda Therapeutics, Inc. ACOR stock rose 14.5% to $2.37.

• Immunogen, Inc. IMGN shares increased by 12.6% to $5.27.

• Citius Pharmaceuticals, Inc. CTXR stock increased by 12.1% to $1.30.

• Novavax, Inc. NVAX stock surged 12.0% to $7.94.

• Zai Lab, Inc. ZLAB stock rose 10.6% to $53.64. The most recent rating by Citigroup, on December 30, is at Buy, with a price target of $84.00.

• Inovio Pharmaceuticals, Inc. INO shares rose 10.5% to $3.80. The most recent rating by PiperJaffray, on January 03, is at Overweight, with a price target of $8.00.

• XTL Biopharmaceuticals, Inc. XTLB stock rose 9.4% to $1.40.

• Harpoon Therapeutics, Inc. HARP shares moved upwards by 8.6% to $15.00. The most recent rating by Canaccord Genuity, on November 25, is at Buy, with a price target of $26.00.

• Rafael Holdings, Inc. RFL stock moved upwards by 8.5% to $22.52.

• Tonix Pharmaceuticals, Inc. TNXP shares moved upwards by 7.6% to $1.41.

• TCR2 Therapeutics, Inc. TCRR stock increased by 7.6% to $13.93. The most recent rating by HC Wainwright & Co., on November 04, is at Buy, with a price target of $19.00.

• Alpine Immune Sciences, Inc. ALPN stock rose 7.6% to $3.33.

• HOOKIPA Pharma, Inc. HOOK shares surged 7.5% to $12.95. The most recent rating by Bank of America, on November 13, is at Buy, with a price target of $14.00.

• Oyster Point Pharma, Inc. OYST shares surged 7.1% to $32.16. The most recent rating by JP Morgan, on November 25, is at Overweight, with a price target of $26.00.

• TRACON Pharmaceuticals, Inc. TCON shares rose 7.0% to $4.00. The most recent rating by H.C. Wainwright, on December 23, is at Buy, with a price target of $18.00.

• ArTara Therapeutics, Inc. TARA shares surged 6.4% to $34.03.

• Stoke Therapeutics, Inc. STOK shares moved upwards by 6.3% to $25.41. The most recent rating by Wedbush, on December 18, is at Outperform, with a price target of $31.00.

• Denali Therapeutics, Inc. DNLI shares surged 6.0% to $24.80.

• Trillium Therapeutics, Inc. TRIL shares surged 5.4% to $3.44.

• Oncolytics Biotech, Inc. ONCY stock rose 5.2% to $3.52.

• Kala Pharmaceuticals, Inc. KALA stock moved upwards by 5.0% to $7.10. According to the most recent rating by Bank of America, on December 17, the current rating is at Neutral.

• Alector, Inc. ALEC stock moved upwards by 4.3% to $23.91. The most recent rating by BTIG, on November 21, is at Buy, with a price target of $28.00.

• CohBar, Inc. CWBR stock moved upwards by 4.2% to $2.72.

• Cerus, Inc. CERS shares rose 4.2% to $4.48. According to the most recent rating by BTIG Research, on November 13, the current rating is at Buy.

• Mersana Therapeutics, Inc. MRSN shares moved upwards by 4.1% to $7.98.

• Cleveland BioLabs, Inc. CBLI stock rose 4.0% to $1.04.

• Outlook Therapeutics, Inc. OTLK shares increased by 4.0% to $1.05.

• Onconova Therapeutics, Inc. ONTX shares rose 3.9% to $0.39.

• Enochian BioSciences, Inc. ENOB shares rose 3.8% to $5.46.

• Akero Therapeutics, Inc. AKRO stock surged 3.8% to $24.19.

• NeuroBo Pharmaceuticals, Inc. NRBO stock moved upwards by 3.7% to $8.49.

• Odonate Therapeutics, Inc. ODT shares rose 3.6% to $28.75.

• NeuBase Therapeutics, Inc. NBSE stock moved upwards by 3.6% to $6.98. The most recent rating by Oppenheimer, on November 21, is at Outperform, with a price target of $14.00.

• Cyclacel Pharmaceuticals, Inc. CYCC stock surged 3.5% to $0.80.

• Fennec Pharmaceuticals, Inc. FENC shares surged 3.3% to $6.36.

• Avid Bioservices, Inc. CDMO stock rose 3.1% to $6.63. According to the most recent rating by First Analysis, on December 10, the current rating is at Strong Buy.

• Entasis Therapeutics Hldg, Inc. ETTX stock rose 3.1% to $5.03.

Losers

• Tetraphase Pharmaceutical, Inc. TTPH shares fell 31.2% to $2.64 during Thursday's regular session. The most recent rating by Gabelli & Co., on October 31, is at Buy, with a price target of $5.00.

• Genprex, Inc. GNPX stock fell 30.2% to $1.32.

• Applied Genetic Tech, Inc. AGTC shares declined 23.4% to $7.55.

• Autolus Therapeutics, Inc. AUTL stock fell 20.1% to $9.97.

• Karuna Therapeutics, Inc. KRTX stock fell 16.3% to $96.51. The most recent rating by Wells Fargo, on January 22, is at Overweight, with a price target of $137.00.

• Therapix Biosciences, Inc. TRPX shares plummeted 16.0% to $0.58.

• Selecta Biosciences, Inc. SELB stock fell 14.6% to $2.99. According to the most recent rating by William Blair, on January 21, the current rating is at Outperform.

• VBI Vaccines, Inc. VBIV shares plummeted 14.4% to $1.25. The most recent rating by Raymond James, on November 14, is at Outperform, with a price target of $3.00.

• Dare Bioscience, Inc. DARE stock fell 14.3% to $1.46.

• Vaxart, Inc. VXRT shares plummeted 11.8% to $0.52.

• Allakos, Inc. ALLK shares fell 10.8% to $74.27.

• RAPT Therapeutics, Inc. RAPT stock declined 9.2% to $42.77. The most recent rating by UBS, on December 04, is at Buy, with a price target of $31.00.

• Esperion Therapeutics, Inc. ESPR stock decreased by 9.0% to $49.46.

• Seelos Therapeutics, Inc. SEEL stock declined 8.9% to $1.23. The most recent rating by H.C. Wainwright, on November 18, is at Buy, with a price target of $2.00.

• Liquidia Technologies, Inc. LQDA stock declined 8.6% to $6.40. The most recent rating by Wedbush, on December 26, is at Outperform, with a price target of $37.00.

• Bicycle Therapeutics, Inc. BCYC shares decreased by 8.5% to $10.34. The most recent rating by Roth Capital, on November 14, is at Buy, with a price target of $17.00.

• DelMar Pharmaceuticals, Inc. DMPI shares declined 8.2% to $0.58.

• Syndax Pharmaceuticals, Inc. SNDX stock plummeted 7.9% to $7.62. The most recent rating by H.C. Wainwright, on January 13, is at Buy, with a price target of $17.00.

• Unum Therapeutics, Inc. UMRX shares decreased by 7.6% to $1.10. The most recent rating by Morgan Stanley, on November 27, is at Overweight, with a price target of $3.00.

• Novan, Inc. NOVN shares fell 7.4% to $0.66. The most recent rating by H.C. Wainwright, on January 06, is at Buy, with a price target of $1.50.

• Axovant Gene Therapies, Inc. AXGT stock decreased by 7.3% to $4.16.

• Infinity Pharmaceuticals, Inc. INFI stock plummeted 7.3% to $1.40. The most recent rating by B. Riley FBR, on November 18, is at Buy, with a price target of $3.50.

• Surface Oncology, Inc. SURF stock plummeted 7.2% to $3.22.

• BioNTech, Inc. BNTX shares plummeted 6.8% to $36.24. The most recent rating by UBS, on January 22, is at Neutral, with a price target of $35.00.

• Aclaris Therapeutics, Inc. ACRS stock plummeted 6.7% to $1.60.

• Advaxis, Inc. ADXS stock plummeted 6.7% to $0.98.

• Arcus Biosciences, Inc. RCUS stock decreased by 6.6% to $9.28. The most recent rating by SunTrust Robinson Humphrey, on November 12, is at Buy, with a price target of $20.00.

• Cancer Genetics, Inc. CGIX shares declined 6.6% to $4.23.

• Zymeworks, Inc. ZYME shares plummeted 6.6% to $46.53. The most recent rating by Wells Fargo, on January 15, is at Overweight, with a price target of $58.00.

• Checkpoint Therapeutics, Inc. CKPT stock decreased by 6.5% to $1.87.

• ChemoCentryx, Inc. CCXI stock fell 6.3% to $39.86. The most recent rating by Canaccord Genuity, on November 26, is at Buy, with a price target of $48.00.

• Avrobio, Inc. AVRO shares declined 5.9% to $21.41. The most recent rating by Wedbush, on November 11, is at Outperform, with a price target of $32.00.

• KemPharm, Inc. KMPH stock fell 5.9% to $0.38. The most recent rating by H.C. Wainwright, on November 20, is at Buy, with a price target of $2.50.

• INmune Bio, Inc. INMB stock fell 5.8% to $4.91. The most recent rating by Roth Capital, on December 19, is at Buy, with a price target of $13.00.

• Personalis, Inc. PSNL shares decreased by 5.7% to $11.36. The most recent rating by Morgan Stanley, on November 15, is at Overweight, with a price target of $16.00.

• ObsEva, Inc. OBSV shares declined 5.7% to $4.16. The most recent rating by H.C. Wainwright, on December 19, is at Buy, with a price target of $40.00.

• Regulus Therapeutics, Inc. RGLS shares declined 5.7% to $1.25.

• Midatech Pharma, Inc. MTP shares decreased by 5.6% to $0.84.

• 89bio, Inc. ETNB shares declined 5.6% to $26.63. The most recent rating by Bank of America, on December 09, is at Neutral, with a price target of $33.00.

• Lexicon Pharmaceuticals, Inc. LXRX shares decreased by 5.6% to $3.56. According to the most recent rating by Gabelli & Co., on December 11, the current rating is at Hold.

• Erytech Pharma, Inc. ERYP stock declined 5.5% to $7.09.

• Fortress Biotech, Inc. FBIO shares declined 5.4% to $2.65. The most recent rating by B. Riley, on December 18, is at Buy, with a price target of $9.00.

• Orgenesis, Inc. ORGS stock fell 5.3% to $4.83.

• Catalyst Biosciences, Inc. CBIO shares declined 5.3% to $6.81.

• Marker Therapeutics, Inc. MRKR stock declined 5.2% to $3.10. The most recent rating by Piper Jaffray, on November 13, is at Overweight, with a price target of $6.00.

• Eloxx Pharmaceuticals, Inc. ELOX shares decreased by 5.1% to $4.43.

• AEterna Zentaris, Inc. AEZS shares fell 5.1% to $1.31.

• Sophiris Bio, Inc. SPHS stock plummeted 5.1% to $0.75.

• Xenon Pharmaceuticals, Inc. XENE stock decreased by 4.9% to $16.00. According to the most recent rating by William Blair, on January 08, the current rating is at Outperform.

• Ovid Therapeutics, Inc. OVID stock decreased by 4.9% to $3.67.

• Monopar Therapeutics, Inc. MNPR shares decreased by 4.9% to $16.80.

• Rexahn Pharmaceuticals, Inc. REXN stock plummeted 4.9% to $2.14.

• Aevi Genomic Medicine, Inc. GNMX stock plummeted 4.8% to $0.21.

• Nabriva Therapeutics, Inc. NBRV shares plummeted 4.8% to $1.49.

• Cellectis, Inc. CLLS shares declined 4.8% to $16.69.

• Blueprint Medicines, Inc. BPMC stock fell 4.8% to $66.49. The most recent rating by Deutsche Bank, on December 10, is at Hold, with a price target of $70.00.

• Kezar Life Sciences, Inc. KZR shares plummeted 4.7% to $3.15.

• Salarius Pharmaceuticals, Inc. SLRX shares fell 4.6% to $2.91.

• Savara, Inc. SVRA shares plummeted 4.6% to $3.33.

• AzurRx BioPharma, Inc. AZRX shares plummeted 4.5% to $1.06.

• Morphic Holding, Inc. MORF shares plummeted 4.5% to $18.56. The most recent rating by BMO Capital, on November 13, is at Outperform, with a price target of $30.00.

• Tyme Technologies, Inc. TYME stock decreased by 4.5% to $1.71.

• Oramed Pharmaceuticals, Inc. ORMP stock decreased by 4.4% to $5.17.

• Neon Therapeutics, Inc. NTGN shares fell 4.4% to $1.74. The most recent rating by Morgan Stanley, on January 21, is at Equal-Weight, with a price target of $2.18.

• Bellerophon Therapeutics, Inc. BLPH stock fell 4.4% to $0.39.

• Sage Therapeutics, Inc. SAGE shares declined 4.2% to $68.80. The most recent rating by SunTrust Robinson Humphrey, on December 06, is at Hold, with a price target of $70.00.

• vTv Therapeutics, Inc. VTVT shares decreased by 4.2% to $2.48.

• UroGen Pharma, Inc. URGN shares decreased by 4.2% to $29.11. The most recent rating by Oppenheimer, on January 13, is at Outperform, with a price target of $52.00.

• Synlogic, Inc. SYBX shares fell 4.2% to $2.77.

• Curis, Inc. CRIS shares declined 4.1% to $1.65.

• Protagonist Therapeutics, Inc. PTGX stock plummeted 4.1% to $7.32.

• Aldeyra Therapeutics, Inc. ALDX shares plummeted 4.0% to $6.00.

• Ritter Pharmaceuticals, Inc. RTTR shares fell 4.0% to $0.19.

• Intellia Therapeutics, Inc. NTLA shares declined 3.9% to $14.06. The most recent rating by Raymond James, on November 01, is at Outperform, with a price target of $24.00.

• NextCure, Inc. NXTC shares plummeted 3.9% to $45.80. The most recent rating by SunTrust Robinson Humphrey, on January 13, is at Buy, with a price target of $78.00.

• Kadmon Holdings, Inc. KDMN stock decreased by 3.9% to $4.45. The most recent rating by Nomura Instinet, on January 10, is at Buy, with a price target of $10.00.

• XOMA, Inc. XOMA shares plummeted 3.9% to $23.25.

• CollPlant Biotechnologies, Inc. CLGN stock declined 3.9% to $10.79.

• IVERIC bio, Inc. ISEE shares decreased by 3.9% to $6.73. The most recent rating by Wedbush, on January 07, is at Outperform, with a price target of $13.00.

• PhaseBio Pharmaceuticals, Inc. PHAS stock declined 3.9% to $5.25.

• Arvinas, Inc. ARVN stock fell 3.8% to $48.80. The most recent rating by PiperJaffray, on January 06, is at Overweight, with a price target of $58.00.

• Vaccinex, Inc. VCNX shares plummeted 3.8% to $5.10.

• Summit Therapeutics, Inc. SMMT stock declined 3.8% to $1.53.

• Intra-Cellular Therapies, Inc. ITCI stock decreased by 3.8% to $24.56. The most recent rating by Canaccord Genuity, on December 24, is at Buy, with a price target of $65.00.

• PDS Biotechnology, Inc. PDSB stock fell 3.8% to $2.51. The most recent rating by H.C. Wainwright, on November 05, is at Buy, with a price target of $7.00.

• Provention Bio, Inc. PRVB stock declined 3.7% to $16.70.

• Genfit, Inc. GNFT shares declined 3.7% to $19.44. The most recent rating by HC Wainwright & Co., on October 31, is at Buy, with a price target of $58.00.

• X4 Pharmaceuticals, Inc. XFOR shares plummeted 3.6% to $9.58. The most recent rating by H.C. Wainwright, on January 07, is at Buy, with a price target of $22.00.

• Gritstone Oncology, Inc. GRTS stock plummeted 3.6% to $9.95.

• Frequency Therapeutics, Inc. FREQ stock decreased by 3.6% to $24.05. According to the most recent rating by Cowen & Co., on October 28, the current rating is at Outperform.

• bluebird bio, Inc. BLUE shares plummeted 3.5% to $90.48. The most recent rating by Oppenheimer, on December 13, is at Outperform, with a price target of $135.00.

• CTI BioPharma, Inc. CTIC shares declined 3.5% to $1.24.

• AC Immune, Inc. ACIU stock decreased by 3.5% to $9.31. The most recent rating by H.C. Wainwright, on December 10, is at Buy, with a price target of $11.00.

• Artelo Biosciences, Inc. ARTL shares decreased by 3.5% to $2.33.

• IDEAYA Biosciences, Inc. IDYA shares declined 3.5% to $9.10.

• Rigel Pharmaceuticals, Inc. RIGL shares declined 3.5% to $2.63. The most recent rating by BMO Capital, on December 09, is at Outperform, with a price target of $8.00.

• NewLink Genetics, Inc. NLNK shares fell 3.4% to $1.97.

• Spero Therapeutics, Inc. SPRO stock fell 3.4% to $9.49. The most recent rating by H.C. Wainwright, on November 05, is at Buy, with a price target of $35.00.

• Jounce Therapeutics, Inc. JNCE stock decreased by 3.4% to $6.66.

• Amicus Therapeutics, Inc. FOLD shares fell 3.4% to $9.37.